[go: up one dir, main page]

WO2009066457A1 - 脂肪酸系イオン液体を有効成分とする外用剤組成物 - Google Patents

脂肪酸系イオン液体を有効成分とする外用剤組成物 Download PDF

Info

Publication number
WO2009066457A1
WO2009066457A1 PCT/JP2008/003409 JP2008003409W WO2009066457A1 WO 2009066457 A1 WO2009066457 A1 WO 2009066457A1 JP 2008003409 W JP2008003409 W JP 2008003409W WO 2009066457 A1 WO2009066457 A1 WO 2009066457A1
Authority
WO
WIPO (PCT)
Prior art keywords
external preparation
fatty acid
preparation composition
ionic liquid
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003409
Other languages
English (en)
French (fr)
Inventor
Toshikazu Yamaguchi
Kenta Kawai
Katsuhiro Yamanaka
Noboru Tatsumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedRx Co Ltd
Original Assignee
MedRx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedRx Co Ltd filed Critical MedRx Co Ltd
Priority to KR1020107013154A priority Critical patent/KR101514342B1/ko
Priority to US12/734,771 priority patent/US8623387B2/en
Priority to CA2705965A priority patent/CA2705965A1/en
Priority to JP2009542480A priority patent/JP5333972B2/ja
Priority to CN2008801249743A priority patent/CN101909651B/zh
Priority to AU2008327436A priority patent/AU2008327436B2/en
Priority to EP08852335A priority patent/EP2223703A4/en
Publication of WO2009066457A1 publication Critical patent/WO2009066457A1/ja
Anticipated expiration legal-status Critical
Priority to US14/073,123 priority patent/US20140066471A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

経皮吸収性の良好な外用剤組成物を提供する。 薬物またはその塩を脂肪酸系イオン液体に溶解させて、薬物の複合イオン組成物を形成させることにより、経皮吸収性に優れた外用剤組成物を作製できる。この外用剤組成物は、液剤、軟膏剤、クリーム剤、硬膏剤等に使用でき、経皮吸収性に優れた製剤品を提供できるようになる。
PCT/JP2008/003409 2007-11-22 2008-11-20 脂肪酸系イオン液体を有効成分とする外用剤組成物 Ceased WO2009066457A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020107013154A KR101514342B1 (ko) 2007-11-22 2008-11-20 지방산계 이온 액체를 유효성분으로 하는 외용제 조성물
US12/734,771 US8623387B2 (en) 2007-11-22 2008-11-20 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
CA2705965A CA2705965A1 (en) 2007-11-22 2008-11-20 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
JP2009542480A JP5333972B2 (ja) 2007-11-22 2008-11-20 脂肪酸系イオン液体を有効成分とする外用剤組成物
CN2008801249743A CN101909651B (zh) 2007-11-22 2008-11-20 包括基于脂肪酸的离子型液体作为活性成分的外用制剂组合物
AU2008327436A AU2008327436B2 (en) 2007-11-22 2008-11-20 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
EP08852335A EP2223703A4 (en) 2007-11-22 2008-11-20 TOPICAL PREPARATION WITH IONIC LIQUID ON FATTY ACID AS AN ACTIVE SUBSTANCE
US14/073,123 US20140066471A1 (en) 2007-11-22 2013-11-06 External preparation composition comprising fatty acid-based ionic liquid as active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-303784 2007-11-22
JP2007303784 2007-11-22
JP2008202639 2008-08-06
JP2008-202639 2008-08-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/734,771 A-371-Of-International US8623387B2 (en) 2007-11-22 2008-11-20 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
US14/073,123 Division US20140066471A1 (en) 2007-11-22 2013-11-06 External preparation composition comprising fatty acid-based ionic liquid as active ingredient

Publications (1)

Publication Number Publication Date
WO2009066457A1 true WO2009066457A1 (ja) 2009-05-28

Family

ID=40667290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003409 Ceased WO2009066457A1 (ja) 2007-11-22 2008-11-20 脂肪酸系イオン液体を有効成分とする外用剤組成物

Country Status (8)

Country Link
US (2) US8623387B2 (ja)
EP (2) EP2223703A4 (ja)
JP (2) JP5333972B2 (ja)
KR (1) KR101514342B1 (ja)
CN (2) CN101909651B (ja)
AU (1) AU2008327436B2 (ja)
CA (1) CA2705965A1 (ja)
WO (1) WO2009066457A1 (ja)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011074567A1 (ja) * 2009-12-15 2011-06-23 帝國製薬株式会社 塩基性消炎鎮痛剤含有経皮吸収製剤
US8232265B2 (en) 2005-10-07 2012-07-31 Board Of Trustees Of The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
JP2012214412A (ja) * 2011-03-31 2012-11-08 Kobayashi Pharmaceutical Co Ltd 油性製剤
JP2012214411A (ja) * 2011-03-31 2012-11-08 Kobayashi Pharmaceutical Co Ltd 油性製剤
WO2012176668A1 (ja) * 2011-06-20 2012-12-27 久光製薬株式会社 リドカイン含有パップ剤
WO2013035850A1 (ja) * 2011-09-08 2013-03-14 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
EP2570122A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation
EP2570115A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570116A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
JP2013139421A (ja) * 2012-01-04 2013-07-18 Yoichi Akama 皮膚外用鎮痛剤、皮膚穿刺時疼痛軽減剤および皮下静脈の血管拡張剤
WO2013191187A1 (ja) * 2012-06-20 2013-12-27 株式会社メドレックス 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物
WO2014024896A1 (ja) * 2012-08-08 2014-02-13 株式会社メドレックス アゴメラチンを含有する貼付剤組成物
WO2015037639A1 (ja) * 2013-09-11 2015-03-19 株式会社 メドレックス テープ剤の新規な基剤組成物
WO2015129527A1 (ja) * 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
JP2015526480A (ja) * 2012-08-24 2015-09-10 インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 治療剤の経皮送達を増強するための化学組成物および方法
JP2016503802A (ja) * 2012-12-21 2016-02-08 テイコク ファーマ ユーエスエー インコーポレーテッド ホルモン及びその他の薬剤を経皮送達するための組成物及び方法
WO2016068336A1 (ja) * 2014-10-30 2016-05-06 旭化成ケミカルズ株式会社 経皮吸収促進剤及び経皮吸収促進助剤
WO2016121996A1 (ja) * 2015-01-30 2016-08-04 株式会社メドレックス 水性外用剤
JP2016535781A (ja) * 2013-11-03 2016-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経皮薬物送達のためのイオン性液体
JP6161142B1 (ja) * 2015-08-29 2017-07-12 株式会社 メドレックス 酸捕捉剤を含有する貼付製剤
JP2017149782A (ja) * 2015-08-29 2017-08-31 株式会社 メドレックス 経皮吸収組成物
US9974858B2 (en) 2015-08-29 2018-05-22 Medrx Co., Ltd Percutaneous absorption composition
JP2018090539A (ja) * 2016-12-05 2018-06-14 王子ホールディングス株式会社 経皮吸収型製剤
US10016502B2 (en) 2015-08-29 2018-07-10 Medrx Co., Ltd Patch preparation containing an acid scavenger
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
US10912834B2 (en) 2016-08-29 2021-02-09 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
WO2021070893A1 (ja) 2019-10-11 2021-04-15 東レ株式会社 温度応答性イオン液体を含む医薬組成物
WO2021192861A1 (ja) 2020-03-26 2021-09-30 国立大学法人九州大学 イオン液体、溶媒、製剤および経皮吸収剤
JPWO2022030631A1 (ja) * 2020-08-07 2022-02-10

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909651B (zh) * 2007-11-22 2013-11-06 美德阿利克斯株式会社 包括基于脂肪酸的离子型液体作为活性成分的外用制剂组合物
US20110092438A1 (en) * 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient
JP5544544B2 (ja) * 2008-08-05 2014-07-09 株式会社 メドレックス 塩基性薬効成分の脂肪酸塩、安息香酸塩を含有する外用剤とその製造方法
JP6893086B2 (ja) 2013-03-13 2021-06-23 エーブリー デニソン コーポレイション 接着特性の向上
WO2016110865A1 (en) * 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
CA2931913C (en) * 2015-06-12 2024-03-19 Kemira Oyj Bitumen separation using ionic liquids comprising unsubstituted or substituted primary, secondary or tertiary amines, pyridines, amidines, guanidines and fatty acids and/or resin acids
US10493049B2 (en) * 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
CN110719777A (zh) * 2017-06-16 2020-01-21 株式会社医药处方 消炎镇痛外用剂
CN109432061B (zh) * 2018-11-09 2020-10-30 北京德默高科医药技术有限公司 含有布洛芬或其结构类似物的多层经皮给药系统
CN112755196B (zh) * 2019-11-01 2024-02-27 华东理工大学 多奈哌齐离子液体
JP7525094B2 (ja) * 2020-04-03 2024-07-30 森田薬品工業株式会社 イオン液体を用いたｂｐａ製剤およびｂｐａを構成物質とするイオン液体
CN115666571B (zh) * 2020-05-20 2024-11-05 美德阿利克斯株式会社 含有阿扑吗啡的经皮吸收型制剂
CN111807985A (zh) * 2020-06-17 2020-10-23 西安医学院 一种利多卡因非甾体抗炎药离子液体及其制备方法
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62103015A (ja) * 1985-10-29 1987-05-13 Sekisui Chem Co Ltd 経皮・経粘膜製剤
JPS62228027A (ja) * 1985-08-26 1987-10-06 Sekisui Chem Co Ltd 経皮・経粘膜製剤
JPH0499716A (ja) 1990-08-17 1992-03-31 Meiji Milk Prod Co Ltd 注射用ｗ／ｏ／ｗ型複合エマルション及びその製造法
JPH0640947A (ja) 1992-07-28 1994-02-15 T T S Gijutsu Kenkyusho:Kk 経皮吸収製剤用組成物および経皮吸収製剤
WO1996004902A1 (en) * 1994-08-09 1996-02-22 Tsumura & Co. Composition of external preparation
JPH08175972A (ja) * 1994-12-28 1996-07-09 Sekisui Chem Co Ltd 経皮吸収製剤
WO2000061120A1 (en) 1999-04-13 2000-10-19 Hisamitsu Pharmaceutical Co., Inc. Preparations for percutaneous absorption
WO2001005381A1 (en) 1999-07-15 2001-01-25 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable preparations
WO2001007018A1 (fr) 1999-07-27 2001-02-01 Hisamitsu Pharmaceutical Co., Inc. Bandes adhesives a usage externe
JP2003528912A (ja) * 2000-03-30 2003-09-30 エルテーエス ローマン テラピー−ジステーメ アーゲー レリセトロンの送出用の経皮治療吸収システム
JP2004507489A (ja) * 2000-08-30 2004-03-11 エルテーエス　ローマン　テラピー−ジステーメ　アーゲー ベンラファキシンを放出するための経皮治療システム
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
JP2005082512A (ja) 2003-09-05 2005-03-31 Medorekkusu:Kk イオン性の薬物の経皮吸収性を高めた外用剤
JP2007008871A (ja) 2005-06-30 2007-01-18 Teikoku Seiyaku Co Ltd 経皮吸収促進組成物
JP2008184402A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) * 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
US4921624A (en) * 1988-06-03 1990-05-01 Ferro Corporation Modified fatty amides and sulfurized fatty oils as lubricant additives
TW206152B (ja) * 1991-03-20 1993-05-21 Kuko Seiyaku Kk
JPH0899832A (ja) * 1994-09-30 1996-04-16 Sunstar Inc 皮膚用乳化化粧料
IT1297139B1 (it) * 1997-12-23 1999-08-03 Pulitzer Italiana Composizioni per la somministrazione transdermica e dermica di sostanze biologicamente attive
JP4285859B2 (ja) * 1999-11-12 2009-06-24 ライオン株式会社 Ｗ／ｏ／ｗ型複合エマルション
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
UY27984A1 (es) * 2002-09-17 2004-04-30 Nippon Boehringer Ingelheim Co Composicion farmaceutica para el suministro por via topica de meloxicam
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
ATE426399T1 (de) * 2004-02-23 2009-04-15 Euro Celtique Sa Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
ES2317138T3 (es) * 2004-11-22 2009-04-16 Hisamitsu Pharmaceutical Co., Inc. Parche transdermico que comprende un agente de diminucion del punto de fusion.
JP4939113B2 (ja) * 2005-06-01 2012-05-23 ニプロパッチ株式会社 貼付剤
CN101909651B (zh) * 2007-11-22 2013-11-06 美德阿利克斯株式会社 包括基于脂肪酸的离子型液体作为活性成分的外用制剂组合物
US20110092438A1 (en) * 2008-03-28 2011-04-21 Angesmg, Inc. Composition for external application comprising transcription factor decoy as active ingredient

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62228027A (ja) * 1985-08-26 1987-10-06 Sekisui Chem Co Ltd 経皮・経粘膜製剤
JPS62103015A (ja) * 1985-10-29 1987-05-13 Sekisui Chem Co Ltd 経皮・経粘膜製剤
JPH0499716A (ja) 1990-08-17 1992-03-31 Meiji Milk Prod Co Ltd 注射用ｗ／ｏ／ｗ型複合エマルション及びその製造法
JPH0640947A (ja) 1992-07-28 1994-02-15 T T S Gijutsu Kenkyusho:Kk 経皮吸収製剤用組成物および経皮吸収製剤
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
WO1996004902A1 (en) * 1994-08-09 1996-02-22 Tsumura & Co. Composition of external preparation
JPH08175972A (ja) * 1994-12-28 1996-07-09 Sekisui Chem Co Ltd 経皮吸収製剤
WO2000061120A1 (en) 1999-04-13 2000-10-19 Hisamitsu Pharmaceutical Co., Inc. Preparations for percutaneous absorption
WO2001005381A1 (en) 1999-07-15 2001-01-25 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable preparations
WO2001007018A1 (fr) 1999-07-27 2001-02-01 Hisamitsu Pharmaceutical Co., Inc. Bandes adhesives a usage externe
JP2003528912A (ja) * 2000-03-30 2003-09-30 エルテーエス ローマン テラピー−ジステーメ アーゲー レリセトロンの送出用の経皮治療吸収システム
US20040001881A1 (en) * 2000-03-30 2004-01-01 Thorsten Selzer Transdermal therapeutic system for delivering lerisetron
JP2004507489A (ja) * 2000-08-30 2004-03-11 エルテーエス　ローマン　テラピー−ジステーメ　アーゲー ベンラファキシンを放出するための経皮治療システム
JP2005082512A (ja) 2003-09-05 2005-03-31 Medorekkusu:Kk イオン性の薬物の経皮吸収性を高めた外用剤
JP2007008871A (ja) 2005-06-30 2007-01-18 Teikoku Seiyaku Co Ltd 経皮吸収促進組成物
JP2008184402A (ja) * 2007-01-29 2008-08-14 Medorekkusu:Kk 外用剤用の低刺激性溶解助剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAZUYOSHI KUBO; TADANORI MAYUMI, FRAGRANCE JOURNAL, vol. 1998-9, 1998, pages 71 - 78
LIANG FANG ET AL., BIOL. PHARM. BULL., vol. 25, 2002, pages 1339 - 1344
See also references of EP2223703A4

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232265B2 (en) 2005-10-07 2012-07-31 Board Of Trustees Of The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
US8802596B2 (en) 2005-10-07 2014-08-12 Board Of Trustees Of The University Of Alabama Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
WO2011074567A1 (ja) * 2009-12-15 2011-06-23 帝國製薬株式会社 塩基性消炎鎮痛剤含有経皮吸収製剤
JP2012214412A (ja) * 2011-03-31 2012-11-08 Kobayashi Pharmaceutical Co Ltd 油性製剤
JP2012214411A (ja) * 2011-03-31 2012-11-08 Kobayashi Pharmaceutical Co Ltd 油性製剤
JP5512891B2 (ja) * 2011-06-20 2014-06-04 久光製薬株式会社 リドカイン含有パップ剤
WO2012176668A1 (ja) * 2011-06-20 2012-12-27 久光製薬株式会社 リドカイン含有パップ剤
US8920831B2 (en) 2011-06-20 2014-12-30 Hisamitsu Pharmaceutical Co., Inc. Lidocaine-containing hydrogel patch
WO2013035850A1 (ja) * 2011-09-08 2013-03-14 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
US20160250156A1 (en) * 2011-09-08 2016-09-01 KM Transderm Ltd. Transdermal preparation
JPWO2013035850A1 (ja) * 2011-09-08 2015-03-23 株式会社 ケイ・エム トランスダーム 経皮吸収製剤
US9707189B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9707187B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570122A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for Enhancing Transdermal Absorption of A Drug and Patch Preparation
EP2570115A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
JP2013060394A (ja) * 2011-09-13 2013-04-04 Nitto Denko Corp 経皮吸収促進用組成物および貼付製剤
JP2013060395A (ja) * 2011-09-13 2013-04-04 Nitto Denko Corp 経皮吸収促進用組成物および貼付製剤
EP2570116A1 (en) 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
JP2013139421A (ja) * 2012-01-04 2013-07-18 Yoichi Akama 皮膚外用鎮痛剤、皮膚穿刺時疼痛軽減剤および皮下静脈の血管拡張剤
US10543275B2 (en) 2012-06-20 2020-01-28 Medrx Co., Ltd. Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
US12016924B2 (en) 2012-06-20 2024-06-25 Medrx Co., Ltd. Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
JPWO2013191187A1 (ja) * 2012-06-20 2016-05-26 株式会社 メドレックス 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物
WO2013191187A1 (ja) * 2012-06-20 2013-12-27 株式会社メドレックス 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物
WO2014024896A1 (ja) * 2012-08-08 2014-02-13 株式会社メドレックス アゴメラチンを含有する貼付剤組成物
JP2015526480A (ja) * 2012-08-24 2015-09-10 インテグアールエックス セラピューティクス， エルエルシーＩｎｔｅｇｕｒｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 治療剤の経皮送達を増強するための化学組成物および方法
JP2016503802A (ja) * 2012-12-21 2016-02-08 テイコク ファーマ ユーエスエー インコーポレーテッド ホルモン及びその他の薬剤を経皮送達するための組成物及び方法
JPWO2015037639A1 (ja) * 2013-09-11 2017-03-02 株式会社 メドレックス テープ剤の新規な基剤組成物
WO2015037639A1 (ja) * 2013-09-11 2015-03-19 株式会社 メドレックス テープ剤の新規な基剤組成物
US9980920B2 (en) 2013-09-11 2018-05-29 Medrx Co., Ltd. Base composition for tape agent
JP2016535781A (ja) * 2013-11-03 2016-11-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経皮薬物送達のためのイオン性液体
US10449254B2 (en) 2013-11-03 2019-10-22 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
JP2019073561A (ja) * 2013-11-03 2019-05-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経皮薬物送達のためのイオン性液体
US11786597B2 (en) 2013-11-03 2023-10-17 The Regents Of The University Of California Ionic liquids for transdermal drug delivery
US10045948B2 (en) 2014-02-27 2018-08-14 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease
JPWO2015129527A1 (ja) * 2014-02-27 2017-03-30 株式会社 メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
WO2015129527A1 (ja) * 2014-02-27 2015-09-03 株式会社メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
WO2016068336A1 (ja) * 2014-10-30 2016-05-06 旭化成ケミカルズ株式会社 経皮吸収促進剤及び経皮吸収促進助剤
WO2016121996A1 (ja) * 2015-01-30 2016-08-04 株式会社メドレックス 水性外用剤
JPWO2016121996A1 (ja) * 2015-01-30 2017-11-09 株式会社 メドレックス 水性外用剤
US11382978B2 (en) 2015-08-29 2022-07-12 Medrx Co., Ltd Percutaneous absorption composition
US10016502B2 (en) 2015-08-29 2018-07-10 Medrx Co., Ltd Patch preparation containing an acid scavenger
JP6161142B1 (ja) * 2015-08-29 2017-07-12 株式会社 メドレックス 酸捕捉剤を含有する貼付製剤
US9974858B2 (en) 2015-08-29 2018-05-22 Medrx Co., Ltd Percutaneous absorption composition
JPWO2017038767A1 (ja) * 2015-08-29 2017-09-07 株式会社 メドレックス 経皮吸収組成物
US10588973B2 (en) 2015-08-29 2020-03-17 Medrx Co., Ltd Percutaneous absorption composition
US10639374B2 (en) 2015-08-29 2020-05-05 Medrx Co., Ltd Patch preparation containing an acid scavenger
JP2017149782A (ja) * 2015-08-29 2017-08-31 株式会社 メドレックス 経皮吸収組成物
EP3756659A1 (en) 2015-08-29 2020-12-30 MEDRx Co., Ltd. Patch preparation containing an acid scavenger
US10912834B2 (en) 2016-08-29 2021-02-09 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
WO2018104772A1 (ja) * 2016-12-05 2018-06-14 王子ホールディングス株式会社 経皮吸収型製剤
JP2018090539A (ja) * 2016-12-05 2018-06-14 王子ホールディングス株式会社 経皮吸収型製剤
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery
WO2021070893A1 (ja) 2019-10-11 2021-04-15 東レ株式会社 温度応答性イオン液体を含む医薬組成物
JPWO2021070893A1 (ja) * 2019-10-11 2021-04-15
KR20220080076A (ko) 2019-10-11 2022-06-14 도레이 카부시키가이샤 온도 응답성 이온 액체를 포함하는 의약 조성물
JP7322895B2 (ja) 2019-10-11 2023-08-08 東レ株式会社 温度応答性イオン液体を含む医薬組成物
WO2021192861A1 (ja) 2020-03-26 2021-09-30 国立大学法人九州大学 イオン液体、溶媒、製剤および経皮吸収剤
KR20220159986A (ko) 2020-03-26 2022-12-05 고쿠리쓰다이가쿠호진 규슈다이가쿠 이온 액체, 용매, 제제 및 경피흡수제
JPWO2022030631A1 (ja) * 2020-08-07 2022-02-10
WO2022030631A1 (ja) * 2020-08-07 2022-02-10 株式会社 メドレックス 組み合わせ製剤

Also Published As

Publication number Publication date
EP3011954A1 (en) 2016-04-27
AU2008327436A1 (en) 2009-05-28
CN101909651A (zh) 2010-12-08
US8623387B2 (en) 2014-01-07
CN101909651B (zh) 2013-11-06
JP5333972B2 (ja) 2013-11-06
JPWO2009066457A1 (ja) 2011-04-07
JP2013173805A (ja) 2013-09-05
CN103239721A (zh) 2013-08-14
EP2223703A1 (en) 2010-09-01
JP5704367B2 (ja) 2015-04-22
EP2223703A4 (en) 2011-01-19
KR20100095446A (ko) 2010-08-30
US20100256174A1 (en) 2010-10-07
CN103239721B (zh) 2016-03-16
CA2705965A1 (en) 2009-05-28
AU2008327436B2 (en) 2013-09-05
US20140066471A1 (en) 2014-03-06
KR101514342B1 (ko) 2015-04-22

Similar Documents

Publication Publication Date Title
WO2009066457A1 (ja) 脂肪酸系イオン液体を有効成分とする外用剤組成物
UA100403C2 (en) Capsule formulation
WO2012034079A3 (en) Macrolide dosage forms
WO2014100777A3 (en) Antimicrobial compositions
WO2011076207A3 (en) Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2009048148A1 (ja) シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤
MX2010004613A (es) Composicion topica.
WO2012035480A3 (en) Pharmaceutical compositions of curcumin
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
WO2012064126A3 (ko) 의료용 접착제 조성물
WO2008146796A1 (ja) ５－メチル－１－フェニル－２－（１ｈ）－ピリドン含有貼付剤
HRP20220626T1 (hr) Otopine bimatoprosta i timolola bez konzervansa
JP2013032405A5 (ja)
WO2009156675A3 (fr) Nouvelles compositions dépigmentantes sous forme d'une composition anhydre sans vaseline et sans élastomère comprenant un dérivé phénolique solubilisé et un rétinoïde
CL2007003318A1 (es) Compuestos derivados de 4,5-difenil-pirrol-2-carboxamida; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento o la prevencion de enfermedades tales como sindrome de abstinencia a una sustancia, t
WO2009084036A3 (en) Composition for treatment of viral infections
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2008146305A3 (en) A pharmaceutical composition having virucidal and spermicidal activity
WO2009015981A3 (en) Treatment of pediatric tumors
HK1209027A1 (en) Vesicular formulations, uses and methods
WO2009008004A3 (en) Sustained release formulations of divalproex sodium
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2009156677A3 (fr) Nouvelles compositions dépigmentantes anhydre comprenant un dérivé phénolique solubilisé

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880124974.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08852335

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2705965

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009542480

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12734771

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008327436

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008852335

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107013154

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008327436

Country of ref document: AU

Date of ref document: 20081120

Kind code of ref document: A